Orphan Drugs Market - Global Industry Analysis, Size, Share,
Growth, Trends and Forecast 2015 - 2023
In a moderately consolidated global orphan drugs market, players are
primarily focused on strategic acquisitions and are strategizing to gain
maximum returns on investments made for R&D of orphan drugs and to
leverage the incentives offered by governments for research on orphan drugs,
according to recent market intelligence by Transparency Market Research. In
this scenario, some of the companies to hold a commanding position in the
global orphan drugs market are Novartis AG, Celgene Corporation, Pfizer
Inc., Alexion Pharmaceuticals Inc., GlaxoSmithKline plc, and Johnson &
The global orphan drugs market is projected to display a healthy 12.1%
CAGR from 2017 to 2025, for the market to reach a valuation of US$318.5
bn by the end of 2025.
Browse Full Research Report:
Vis-à-vis revenue, in 2016, oncology stood as the dominant segment based on
disease type, and is expected to hold on to its dominant position over the
forecast period. The increasing genetic mutations and the increasing burden
of rare cancers are attributed to the growth of this segment.
In terms of product type, biologic products led the market in 2016 on the
basis of revenue. The segment is expected to display a significant CAGR
over the forecast period backed by factors such as high efficacy, fewer side
effects, and difficulty to develop generic versions of these drugs. Hospital
pharmacies led the global orphan drugs market in terms of revenue in 2016
amongst all distribution channel segments.
North America held the leading share of the orphan drugs market in 2016.
Within North America, the U.S. is a leading domestic market contributing
substantial revenue to this market.
As per an analyst at TMR, the global orphan drugs market is anticipated to
expand at a significant growth rate on account of a number of factors.
Amongst all, high return on investments for the development of orphan drugs
is a key one. The development of phase- III orphan drugs costs over 50%
more than the cost of development of non-orphan drugs. The return on
investments is estimated to be over 1.2 times greater for phase- III orphan
drugs than non-orphan drugs.
In developed countries, strong focus on research and development of orphan
drugs, which receives government aid, tax credits, and fee waivers is
contributing to the growth of this market. As per records of the Research
Office Legislative Council Secretariat, there are more than 30 million
individuals suffering from rare diseases in the U.S. As a result, 4,171 drugs
have received orphan drug status in the U.S., which is attracting drug
manufacturers to invest in this market.
Furthermore, increasing number of rare diseases that are related to genetic
reasons leading to investments for drug development of these diseases is
benefitting the orphan drugs market. As per statistics of Global Genes, a nonprofit organization, more than 7,000 types of rare diseases have been
identified globally. At present, more than 300 million people worldwide are
estimated to be affected by rare diseases that calls for considerable
production of orphan drugs.
Browse Full Press Release:
Transparency Market Research (TMR) is a global market intelligence
company providing business information reports and services. The
company’s exclusive blend of quantitative forecasting and trend analysis
provides forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use proprietary
data sources and various tools and techniques to gather and analyze
TMR’s data repository is continuously updated and revised by a team of
research experts so that it always reflects the latest trends and information.
With extensive research and analysis capabilities, Transparency Market
Research employs rigorous primary and secondary research techniques to
develop distinctive data sets and research material for business reports.
Transparency Market Research
90 State Street, Suite 700,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
Email: [email protected]